EP4378942A1 — Crystal form of a pde3/4 inhibitor
Assigned to Sandoz AG · Expires 2024-06-05 · 2y expired
What this patent protects
The present invention relates to a novel crystal of ensifentrine free base and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said ensifentrine free base crystal, at least one pharmaceutically acceptable excipient. …
USPTO Abstract
The present invention relates to a novel crystal of ensifentrine free base and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said ensifentrine free base crystal, at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and symptoms of a COVID-19 infection.
Drugs covered by this patent
- Ohtuvayre (ENSIFENTRINE) · Verona Pharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.